Literature DB >> 26435427

Cost disparity between health care systems--it's not the surgeons: A cost analysis of thyroid cancer care between the United States and France.

Brendan M Finnerty1, Laurent Brunaud2, Eric Mirallie3, Caitlin McIntyre4, Anna Aronova4, Thomas J Fahey4, Rasa Zarnegar4.   

Abstract

BACKGROUND: The cost disparity between the United States and other advanced health care systems, including France, is expanding. In this report we identified the management of papillary thyroid cancer (PTC) that contribute to reimbursement disparity.
METHODS: A tri-institutional, retrospective review included 200 patients with PTC (100 from the United States, 100 from France) treated by total thyroidectomy with/without central neck dissection. A cost model was generated incorporating perioperative management variables (within 1 year) and their reimbursement rates according to the 2014 US Medicare and French government fee-schedules.
RESULTS: In the United States, total thyroidectomy with central neck dissection was more frequent (92% vs 35%, P < .001), median duration of stay was less (1 vs 3 days, P < .001), and use of radioactive iodine was less (66% vs 93%, P < .001), although Thyrogen stimulation was more prevalent (100% vs 43%, P < .001). Overall, the median cost per patient was greater in the United States ($14,069 vs $4,590, P < .001). Reimbursements to the hospital facility accounted for 70% of the disparity, despite lesser durations of stay. Nuclear medicine accounted for 19%, mostly from Thyrogen reimbursement despite less use of radioactive iodine. Surgeon fees accounted for 6%, followed by office visits, laboratory/imaging, anesthesia/pathology fees, and medications.
CONCLUSION: The costs of management of PTC are substantially greater in the US compared with France. Efforts to decrease this disparity should focus on reimbursements for hospital facility and use of nuclear medicine imaging.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26435427     DOI: 10.1016/j.surg.2015.06.049

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  5 in total

1.  Thyroid Incidentalomas in Association With Low-Dose Computed Tomography in the National Lung Screening Trial.

Authors:  Holli A Loomans-Kropp; Barbara K Dunn; Barnett S Kramer; Paul Pinsky
Journal:  Am J Epidemiol       Date:  2020-01-31       Impact factor: 4.897

2.  Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998-2012.

Authors:  Emanuele Crocetti; Veronica Mattioli; Carlotta Buzzoni; Silvia Franceschi; Diego Serraino; Salvatore Vaccarella; Stefano Ferretti; Susanna Busco; Ugo Fedeli; Massimo Varvarà; Fabio Falcini; Manuel Zorzi; Giuliano Carrozzi; Walter Mazzucco; Cinzia Gasparotti; Silvia Iacovacci; Federica Toffolutti; Rossella Cavallo; Fabrizio Stracci; Antonio G Russo; Adele Caldarella; Stefano Rosso; Antonino Musolino; Lucia Mangone; Claudia Casella; Mario Fusco; Giovanna Tagliabue; Daniela Piras; Rosario Tumino; Linda Guarda; Ylenia M Dinaro; Silvano Piffer; Pasquala Pinna; Guido Mazzoleni; Anna C Fanetti; Luigino Dal Maso
Journal:  Cancer Med       Date:  2021-09-17       Impact factor: 4.452

Review 3.  Differentiated Thyroid Cancer: A Health Economic Review.

Authors:  Klaas Van Den Heede; Neil S Tolley; Aimee N Di Marco; Fausto F Palazzo
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

4.  Thyroid Cancer Metabolism: A Review.

Authors:  Kurren S Gill; Patrick Tassone; James Hamilton; Nikolaus Hjelm; Adam Luginbuhl; David Cognetti; Madalina Tuluc; Ubaldo Martinez-Outschoorn; Jennifer M Johnson; Joseph M Curry
Journal:  J Thyroid Disord Ther       Date:  2016-01-14

5.  Using Watershed Boundaries to Map Adverse Health Outcomes: Examples From Nebraska, USA.

Authors:  Brittany Corley; Shannon Bartelt-Hunt; Eleanor Rogan; Donald Coulter; John Sparks; Lorena Baccaglini; Madeline Howell; Sidra Liaquat; Rex Commack; Alan S Kolok
Journal:  Environ Health Insights       Date:  2018-01-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.